Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study.

MLA

Hyeon Gyu Yi, et al. “Allogeneic Clonal Mesenchymal Stem Cell Therapy for Refractory Graft-versus-Host Disease to Standard Treatment: A Phase I Study.” Korean Journal of Physiology & Pharmacology, vol. 20, no. 1, Jan. 2016, pp. 63–67. EBSCOhost, https://doi.org/10.4196/kjpp.2016.20.1.63.

APA

Hyeon Gyu Yi, Seung-Ah Yahng, Inho Kim, Je-Hwan Lee, Chang-Ki Min, Jun Hyung Kim, Chul Soo Kim, & Sun U. Song. (2016). Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean Journal of Physiology & Pharmacology, 20(1), 63–67. https://doi.org/10.4196/kjpp.2016.20.1.63

Chicago

Hyeon Gyu Yi, Seung-Ah Yahng, Inho Kim, Je-Hwan Lee, Chang-Ki Min, Jun Hyung Kim, Chul Soo Kim, and Sun U. Song. 2016. “Allogeneic Clonal Mesenchymal Stem Cell Therapy for Refractory Graft-versus-Host Disease to Standard Treatment: A Phase I Study.” Korean Journal of Physiology & Pharmacology 20 (1): 63–67. doi:10.4196/kjpp.2016.20.1.63.